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OBJECTIVE—Tall-like receptor (TLR)4 has been implicated in
the pathogenesis of free fatty acid (FFA)-induced insulin resis-
tance by activating inﬂammatory pathways, including inhibitor of
B( I B)/nuclear factor B (NFB). However, it is not known
whether insulin-resistant subjects have abnormal TLR4 signaling.
We examined whether insulin-resistant subjects have abnormal
TLR4 expression and TLR4-driven (IB/NFB) signaling in skel-
etal muscle.
RESEARCH DESIGN AND METHODS—TLR4 gene expres-
sion and protein content were measured in muscle biopsies in 7
lean, 8 obese, and 14 type 2 diabetic subjects. A primary human
myotube culture system was used to examine whether FFAs
stimulate IB/NFB via TLR4 and whether FFAs increase TLR4
expression/content in muscle.
RESULTS—Obese and type 2 diabetic subjects had signiﬁcantly
elevated TLR4 gene expression and protein content in muscle. TLR4
muscle protein content correlated with the severity of insulin
resistance. Obese and type 2 diabetic subjects also had lower IB
content, an indication of elevated IB/NFB signaling. The increase
in TLR4 and NFB signaling was accompanied by elevated expres-
sion of the NFB-regulated genes interleukin (IL)-6 and superoxide
dismutase (SOD)2. In primary human myotubes, acute palmitate
treatment stimulated IB/NFB, and blockade of TLR4 prevented
the ability of palmitate to stimulate the IB/NFB pathway. In-
creased TLR4 content and gene expression observed in muscle
from insulin-resistant subjects were reproduced by treating myo-
tubes from lean, normal-glucose-tolerant subjects with palmitate.
Palmitate also increased IL-6 and SOD2 gene expression, and this
effect was prevented by inhibiting NFB.
CONCLUSIONS—Abnormal TLR4 expression and signaling, possi-
bly caused by elevated plasma FFA levels, may contribute to the
pathogenesis of insulin resistance in humans. Diabetes 57:2595–
2602, 2008
T
he mechanism(s) by which free fatty acids
(FFAs) cause insulin resistance is not fully un-
derstood. Considerable evidence suggests that
the deleterious effect of FFAs on insulin action is
caused by intramyocellular FFA metabolites that stimulate
inﬂammatory pathways leading to impaired insulin signal-
ing/action (1). However, recent reports demonstrate that
FFAs directly can stimulate plasma membrane receptors
(2,3), suggesting an alternate model in which FFAs cause
insulin resistance by stimulating inﬂammatory pathways
through the direct activation of plasma membrane recep-
tors. Consistent with this hypothesis, FFAs have been
shown to bind to toll-like receptor (TLR)4 (4), a transmem-
brane receptor, and TLR4-driven inﬂammatory cascades,
such as the inhibitor of B( I B)/nuclear factor B (NFB)
pathway, are implicated in the pathogenesis of insulin
resistance (5–7).
TLRs play an important role in the innate immune
system by activating inﬂammatory pathways in response
to microbial agents (8). TLR4 functions as the receptor for
lipopolysaccharide (LPS) of gram-negative bacterial cell
walls (8). Saturated FFAs acylated in the lipid A moiety of
LPS are essential for the biological activity of LPS (9). In
mononuclear cells/monocytes, saturated FFAs are potent
activators of TLR4 signaling, whereas unsaturated FFAs
do not stimulate this pathway (10). After LPS binds to
TLR4, and its co-receptors CD14 and MD-2, the adaptor
protein myeloid differentiation factor 88 (MyD88) is re-
cruited to the Toll/interleukin (IL)-1 receptor (TIR) do-
main of the TLR4 receptor (11). The interaction between
TLR4 and MyD88 leads to the autophosphorylation of
IL-1R–associated kinase (IRAK) (11). When IRAK becomes
activated, it interacts with tumor necrosis factor (TNF)-
associated factor 6 (TRAF6), leading to stimulation of the
kinase complex IB kinase (IKK), which phosphorylates
I. Phosphorylation of IB by IKK triggers the degrada-
tion of I by the proteosome, causing the liberation of
NFB from IB. NFB then translocates into the nucleus,
where it stimulates the transcription of numerous inﬂam-
matory genes including IL-6 (12) and superoxide dis-
mutase (SOD)2 (13).
Most of the data implicating FFAs as ligands of TLR4
have been obtained in inﬂammatory cells and mononu-
clear cells/monocytes (10). However, recent studies have
provided evidence that FFAs stimulate TLR4 signaling in
conventional insulin-target tissues such as fat (14,15) and
muscle (16,17). TLR4 was found to be highly expressed in
3T3 L1 adipocytes and fat tissue from mice (14,15). In
addition, TLR4 gene expression was higher in adipose
tissue from insulin-resistant (high-fat–fed, db/db, and
ob/ob) mice compared with normal animals (14,15). More-
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DIABETES, VOL. 57, OCTOBER 2008 2595over, the ability of a lipid infusion to activate the IB/NFB
pathway in adipose tissue (14) and to inhibit insulin-
stimulated whole-body glucose disposal (14,17) is reduced
in TLR4 null mice. Because muscle is the major site of
insulin-stimulated glucose disposal (18), this important
ﬁnding implies that TLR4 is also functional in skeletal
muscle. Indeed, muscles from mice carrying an inactivat-
ing mutation on TLR4 are prevented from developing
lipid-induced insulin resistance (16). Whereas these data
obtained from animal and tissue culture models clearly
implicate TLR4 in the pathogenesis of insulin resistance, it
remains unknown whether this pathway functions abnor-
mally and contributes to insulin resistance in muscle from
human subjects. Therefore, the purpose of this study was
to examine whether insulin-resistant subjects have abnor-
mal TLR4 expression and signaling in muscle and to
determine whether TLR4 plays a role in the stimulation of
IB/NFB caused by FFAs. We hypothesize that 1) insulin-
resistant subjects have abnormal function of TLR4 in
muscle, and 2) TLR4 is involved in FFA-induced IB/NFB
stimulation in human muscle.
RESEARCH DESIGN AND METHODS
We recruited 7 lean, 8 obese nondiabetic, and 14 obese subjects with type 2
diabetes. All subjects were sedentary and had stable body weight for 6 months
before study. Each subject underwent a medical history, physical examina-
tion, screening laboratory tests, and an oral glucose tolerance test (OGTT).
Lean and obese nondiabetic subjects had no family history of type 2 diabetes
and were normal glucose tolerant. None of the lean or obese subjects were
taking any medication. Three type 2 diabetic subjects were taking glipizide,
which was withdrawn 3 days before the OGTT. Nine type 2 diabetic subjects
were treated with diet alone. Other than glipizide, no subject was taking any
medication known to affect glucose metabolism. The study was approved by
the institutional review board of the University of Texas Health Science
Center at San Antonio (UTHSCSA), and all subjects gave written consent.
OGTT. Plasma glucose and FFA levels were measured at baseline and every
15 min for 2 h after the ingestion of 75 g glucose. Plasma insulin was measured
at baseline, and the severity of insulin resistance was estimated using the
homeostasis model assessment (HOMA) index (19).
Muscle biopsies. Subjects reported to the clinical research center at 8:00 A.M.
after an overnight fast and refrained from any exercise for 48 h before the
muscle biopsy. Subjects rested for 30 min before a vastus lateralis muscle
biopsy (20). The muscle was debrided of adipose and connective tissue and
immediately (within 5 s after the biopsy) frozen in liquid nitrogen.
Generation of primary myotubes. Primary skeletal muscle cells were
grown from satellite cells obtained from the muscle tissue based on the
protocol by Henry et al. (21), with minor modiﬁcations. All donors were lean
and had a normal glucose tolerance test. After excision, the muscle tissue
(100 mg) was immediately placed in 15 ml Ham’s F-12 medium at 4°C. After
removing excess fat and connective tissue, the samples were digested in 0.05%
trypsin, 0.1% collagenase, and 1.5% BSA, pH 7.4, for 30 min at 37°C with
agitation. After 30 min of incubation, 10% FBS was added and the tissue was
centrifuged at 80g for 10 min. Cell pellets were resuspended with 20%
-minimal essential medium (MEM) containing penicillin (200 units/ml)/
streptomycin (200 mg/ml). Cells were plated on 100-mm dishes and incubated
f o r1ht oremove ﬁbroblasts. The myoblasts then were grown to conﬂuence
in 75 cm
2 collagen-coated ﬂasks with 20% -MEM for 5–7 days and subse-
quently seeded in 75 cm
2 ﬂasks for another 5 days. For all individual
experiments, myoblasts were seeded in six-well culture dishes (9.6 cm
2/well)
at a density of 20,000 cells/well. When myoblasts reached 80–90% conﬂuence,
the cells were fused for 4–7 days in -MEM with 2% FBS. Cells displayed the
typical features of differentiated myotubes: elongated, multinucleated cells
expressing myosin heavy chain by Western blotting.
Preparation of palmitate solution. Stocks of 8 mmol/l palmitate and 10.5%
fatty acid–free BSA (low endotoxin grade; Sigma, St. Louis, MO) were prepared as
described (22).
Acute IB/NFB pathway stimulation in myotubes. Dose-response and
time-course experiments were performed by treating human myotubes with
200 or 400 mol/l palmitate at different time points. Palmitate at a 400-mol/l
concentration was used because it has been shown to activate the IB/NFB
pathway in C2C12 cells (23). After treatment, cells were lysed in lysis buffer
(20 mmol/l Tris, pH 7.5, 5 mmol/l EDTA, 10 mmol/l Na3PO4, 100 mmol/l NaF,
2 mmol/l Na3VO4,1 %N P4 0 ,1 0mol/l leupeptin, 3 mmol/l Benzamidine, 10
g/ml aprotinin, and 1 mmol/l phenylmethylsulfonyl ﬂuoride), and the lysates
were stored in liquid nitrogen. To examine whether TLR4 is involved in
palmitate-induced IB/NFB activation, myotubes were ﬁrst incubated in
media with a TLR4 neutralizing antibody (10 g/ml) or an isotype control (10
g/ml) (both from eBioscience, San Diego, CA) for1ha troom temperature.
The TLR4 neutralizing antibody (10 g/ml) has been shown to block TLR4-
driven inﬂammatory responses (16,24). After blocking TLR4, the myotubes
were washed once with PBS, treated with 400 mol/l palmitate for 1 h, and
lysed. To determine whether other TLRs, such as TLR2, play a role in FFA
stimulation of IB/NFB, similar experiments were done with a TLR2 neu-
tralizing antibody (10 g/ml) (eBioscience) (25). In addition, we determined
the effect of a different saturated fatty acid, 400 mol/l stearate (Sigma), as
well as an unsaturated fatty acid, 400 mol/l linoleate (Sigma), by treating
myotubes for 1 h and measuring IB phosphorylation.
IKK kinase activity assay. Myotubes were treated with 400 mol/l palmi-
tate, 100 ng/ml LPS (Sigma), or 20 ng/ml human TNF- (R&D Systems,
Minneapolis, MN) for 1 h, harvested in lysis buffer, and frozen in liquid
nitrogen. After thawing, lysates were then centrifuged at 14,000g for 20 min at
4°C and the supernatants (250 g protein) were immunoprecipitated with an
anti-human IKK antibody (Epitomics, Burlingame, CA) and protein A beads.
Immunoprecipitates were washed twice in lysis buffer and twice in wash
buffer (50 mmol/l Tris, pH 7.4, 0.5 mol/l NaCl, and 0.1 mmol/l EGTA). Kinase
reactions were performed in 50 mmol/l Tris, pH 7.4, 0.2 mmol/l IKK peptide
(Upstate Biotechnology, Lake Placid, NY), 1 mmol/l dithiothreitol, 10 mmol/l
MgCl2, 0.1 mmol/l EGTA, and 0.1 mmol/l ATP (3 Ci [
32P]ATP) in a ﬁnal
volume of 50 l for 20 min at 30°C. At the end of the reaction, a 25-l aliquot
was removed and spotted on Whatman P81 paper. The papers were washed
six times in ice-cold 1% phosphoric acid and once with acetone at room
temperature. Radioactivity was quantitated with a scintillation counter.
Chronic palmitate treatment. Myotubes were treated with 200 mol/l
palmitate, 100 nmol/l insulin (Humulin; Eli Lilly, Indianapolis, IN), 20 ng/ml
human TNF-, or 100 ng/ml IL-6 (R&D Systems) for 72 h. TNF- and IL-6, at
the concentrations used, have been shown to elicit an inﬂammatory response
in muscle cells (26,27). Myotubes then were lysed, and TLR4 protein content
was measured by Western blotting.
Simulation of TLR4 gene expression by palmitate and lipid A. Myotubes
were incubated for 6 h with 200 mol/l palmitate or with the speciﬁc TLR4
agonist synthetic (from E. coli) monophosphoryl lipid A (10 g/ml) (Invivo-
gen, San Diego, CA), and mRNA expression was measured by real-time PCR.
Adenoviral-mediated transduction. Myotubes were ﬁrst infected with
adeno-IB-superrepressor (tagged with HA) or adeno–green ﬂuorescent pro-
tein (GFP) (both at 1  10
8 plaque-forming units; Vector Biolabs, Philadelphia,
PA) for 4 h, achieving a 95% transduction efﬁciency based on ﬂuorescence
microscopy. To examine the effect of palmitate on IL-6, SOD2, and TLR4 gene
expression, 48 h after the transduction, myotubes were treated with 200
mol/l palmitate for 6 h, and mRNA gene expression was measured by
real-time PCR. The IBSS32/36AA (superrepressor) mutant functions as a
potent inhibitor of NFB because mutating serines 32 and 36 for alanine
prevents phosphorylation and dissociation of IB from NFB (28).
Quantitative real-time PCR. Total RNA was extracted with Trizol solution
(Sigma) and puriﬁed with RNeasy and DNase I treatment (Qiagen, Chats-
worth, CA). An Agilent Bioanalyzer was used to check RNA quality. Quanti-
tative real-time PCR was performed on an ABI PRISM 7900HT System
(Applied Biosystems, Foster City, CA) using TaqMan One-Step RT-PCR Master
Mix Reagents and Assay On-Demand primer/probes (TLR4: Hs00152939_m1,
SOD2: Hs00167309_m1, EMR1: Hs00173562_m1). TLR2 expression was deter-
mined using the following primers/probe: forward primer: 5-CAATGATGCTG
CCATTCTCAT-3, reverse primer: 5-ATTATCTTCCGCAGCTTGCA-3, probe:
5-CATTGAGAAAAAAGCCATTCCCCAGCG-3. IL-6 expression was determined
using forward primer: 5-GGTACATCCTCGACGGCATCT-3, reverse primer:
5-GTGCCTCTTTGCTGCTTTCAC-3, probe: 5-TGTTACTCTTGTTACATGTCT
CCTTTCTCAGGGCT-3. Each sample was run in duplicate, and the quantity of
mRNA for each gene of interest was normalized to that of 18S ribosomal RNA
using the comparative (2
	

CT) method (29).
Western blotting. Muscle tissue samples were homogenized as previously
described (30). Proteins were separated by 10% SDS-PAGE and transferred to
nitrocellulose membranes. After blocking the membranes, these were incu-
bated overnight with a primary antibody against TLR4 (Santa Cruz Biotech-
nology, Santa Cruz, CA), phospho-IB (Cell Signaling, Danvers, MA), IB
(Cell Signaling), or -actin (Cell Signaling). Bound antibodies were detected
with a secondary antibody (anti-rabbit immunoglobulin–horseradish peroxi-
dase–linked antibody) using enhanced chemiluminescence reagents. Bands
were quantitated with ImageTool (UTHSCSA). Detection of TLR2 protein in
muscle was attempted using antibodies from eBioscience, Cell Signaling,
Santa Cruz Biotechnology, and Imgenex (San Diego, CA). Detection of
the monocyte/macrophage marker epidermal growth factor–like module
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NFB activity. Binding activity of the p65 NFB subunit was measured in cell
lysates using an enzyme-linked immunosorbent assay (ELISA) kit (Active
Motif, Carlsbad, CA).
Laboratory analyses. Plasma insulin was measured by radioimmunoassay
(Diagnostic Products, Los Angeles, CA), glucose by the glucose oxidase
method on a Beckman analyzer, and A1C using a DCA2000 analyzer (Bayer,
Tarrytown, NY). FFA concentration was determined with a colorimetric
method (Wako, Nuess, Germany). Plasma TNF- and IL-6 concentrations were
measured using an ELISA (R&D Systems).
Statistical analysis. All data are expressed as means  SE. Comparison of
data between the lean, obese, and type 2 diabetes groups was done using
one-way ANOVA, followed by Tukey post hoc analysis. The effect of palmitate
on IKK and IB was assessed using one-way ANOVA with repeated measures.
The effect of the TLR4-blocking antibodies and the IB supperrepressor on
palmitate-induced TLR4 pathway stimulation was assessed by two-way
ANOVA. The effect of palmitate on TLR4 protein/gene expression and the
effect of monophosphoryl lipid A on TLR4 gene expression were determined
using the Student’s t test. Analyses were performed using SigmaStat software.
RESULTS
Subject characteristics. Clinical and laboratory charac-
teristics of the subjects are shown in Table 1. All groups
were closely matched for age. Type 2 diabetic and obese
subjects were well matched for BMI, and both groups
were more obese than the lean normal-glucose-tolerant
group (P  0.05). Subjects with type 2 diabetes had higher
fasting plasma glucose concentrations, glucose area under
the curve (AUC) during OGTT, and A1C levels compared
with the obese and lean subjects (P  0.05). Obese and
type 2 diabetic subjects were more insulin resistant than
lean subjects, based on a higher HOMA index and plasma
insulin concentration (P  0.05). The subjects from the
obese and type 2 diabetes groups also had higher fasting
plasma FFA concentrations and FFA AUC during the
OGTT compared with lean control subjects (P  0.05).
Plasma concentrations of TNF- and IL-6 were signiﬁ-
cantly elevated in the type 2 diabetic subjects (P  0.05),
and there was a tendency for higher TNF- and IL-6 levels
in obese versus lean subjects (P 
 0.1 for both cytokines).
Elevated TLR4 gene expression and protein content
in insulin-resistant subjects. TLR4 gene expression was
signiﬁcantly increased in the muscle of the obese nondia-
betic and type 2 diabetic subjects (4.8- and 3.2-fold,
respectively; P  0.05) compared with lean subjects (Fig.
1A). Collectively, in the three groups, absolute TLR4
mRNA levels correlated with fasting plasma FFA concen-
trations (r 
 0.37, P 
 0.05) and FFA AUC during OGTT
(r 
 0.41, P 
 0.03). To examine whether increased TLR4
gene expression in obese and type 2 diabetic subjects was
reﬂected at the protein level, we measured TLR4 muscle
protein content by Western analysis using an antibody
targeted against the epitope corresponding to amino acids
242–321 of the internal region of human TLR4. Using this
antibody, TLR4 migrated as a single 100-kDa band. To
conﬁrm the speciﬁcity of the antibody, human embryonic
kidney cell lysates overexpressing human TLR4 tagged
with yellow ﬂuorescent protein (provided by Dr. Andrei
Medvedev, University of Maryland) were immunoprecipi-
tated with an anti-GFP antibody (Invitrogen, Carlsbad, CA)
and blotted with anti-TLR4 (not shown). Consistent with
the increases in TLR4 gene expression, obese and type 2
diabetic subjects had 2.8- and 2.2-fold higher TLR4 mus-
cle protein content than lean subjects (P  0.05) (Fig.
1B), and there was a positive correlation (r 
 0.57, P 

0.003) between the HOMA index of insulin resistance
(HOMA-IR) and TLR4 content (Fig. 1C).
Similar to TLR4, the gene expression of TLR2 was
signiﬁcantly elevated in muscle from obese and type 2
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FIG. 1. TLR4 and TLR2 gene expression and protein content. TLR4
mRNA expression (A) and protein content (B) were measured in lean,
obese, and type 2 diabetic (T2DM) subjects. Data are means  SE in 7
lean, 8 obese, and 14 type 2 diabetic subjects in A and 6 lean, 8 obese,
and 10 type 2 diabetic subjects in B (protein extracts were not
available for all subjects). C: Correlation between TLR4 content and
HOMA-IR. D: TLR2 mRNA expression in 7 lean, 8 obese, and 14 type 2
diabetic subjects. *P < 0.05 vs. lean. E: Direct Western blotting in
muscle from three lean and three type 2 diabetic subjects using an
antibody against human TLR2 (eBiosciences). A band corresponding to
TLR2 was detected in mononuclear cells (MNCs) isolated from two
subjects.
TABLE 1
Clinical and laboratory characteristics
Lean Obese
Type 2
diabetes
n 781 4
Sex (M/F) 4/3 3/5 5/9
Age (years) 45  24 4  35 2  3
BMI (kg/m
2) 25.3  0.7 30.5  0.6* 31.8  1.2*
Fasting glucose (mmol/l) 5.4  0.2 5.6  0.1 7.8  0.6*†
Glucose AUC during
OGTT (mg/dl  2 h) 120  11 121  8 230  18*†
Fasting insulin (pmol/l) 19  49 2  16* 86  16*
HOMA-IR 0.6  0.1 2.0  0.3* 2.1  0.4*
Fasting FFAs (mol/l) 351  37 479  59* 750  29*†
FFA AUC during OGTT
(mol/l  2 h) 22.8  1.1 31.3  3.3* 55.9  3.7*†
TNF- (pg/ml) 1.26  0.10 1.63  0.30 2.13  0.32*
IL-6 (pg/ml) 1.17  0.15 1.91  0.40 2.42  0.33*
Data are means  SE. *P  0.05 vs. lean; †P  0.05 vs. obese.
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 0.05) (Fig. 1D). Nonetheless, we
were not able to detect TLR2 protein in muscle from
human subjects (diabetic and nondiabetic) by direct West-
ern blotting, despite using several commercially available
antibodies. Figure 1E shows that, in contrast to muscle,
human mononuclear cells highly express TLR2 protein.
TLR4-driven signaling. We examined whether increased
TLR4 gene expression and protein content in insulin-
resistant subjects was associated with abnormal TLR4
signaling by measuring abundance of IB. Obese and
type 2 diabetic subjects had decreased IB content in
muscle (Fig. 2A). Because phosphorylation of IBb yI K K
leads to IB degradation, a reduction in IB abundance is
considered to indicate activation of the IB/NFB pathway
(31). IB abundance inversely correlated with fasting
plasma FFA concentrations (r 
	 0.6, P 
 0.005) and FFA
AUC during OGTT (r 
	 0.46, P 
 0.03) and tended to
correlate negatively with the HOMA index (r 
	 0.34, P 

0.1). Currently, we are investigating whether direct mea-
surement of IKK activity (which was not measured be-
cause of insufﬁcient protein) has a stronger (negative)
correlation with insulin sensitivity measured with the
insulin clamp.
We also determined the expression of IL-6 and SOD2,
genes that are highly regulated by NFB (12,13), in muscle
from obese and type 2 diabetic subjects. As shown in Figs.
2B and C, obese and type 2 diabetic subjects had elevated
IL-6andSOD2geneexpressioncomparedwithleannormal-
glucose-tolerant subjects (P  0.05). Collectively, these re-
sults indicate that insulin-resistant subjects have increased
TLR4 expression/content and TLR4-driven signaling.
FFAs acutely stimulate TLR4-driven signaling. To
explore whether FFAs directly stimulate TLR4-driven sig-
naling in human muscle, we used a primary muscle cell
culture system using satellite cells obtained from lean,
normal-glucose-tolerant subjects. Treatment with 200 and
400 mol/l palmitate decreased IB abundance (Fig. 3A)
and increased IB phosphorylation within 15 min (Fig.
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FIG. 3. Effect of FFAs on IB and IKK activity. Human myotubes were
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FIG. 2. TLR4 signaling. IB protein abundance (A) and mRNA expres-
sion of IL-6 (B) and SOD2 (C) were measured in lean, obese, and type
2 diabetic (T2DM) subjects. Data are means  SE. *P < 0.05; †P  0.05
vs. lean.
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palmitate treatment. Treatment with 100 mol/l palmitate
for up to 240 min did not consistently increase IB
phosphorylation (not shown). In line with the increases in
IB phosphorylation, palmitate signiﬁcantly increased
IKK kinase activity (Fig. 3C). Stearate, another saturated
fatty acid, also stimulated IB/NFB signaling, whereas
the unsaturated fatty acid linoleate did not affect this
pathway (Fig. 3D). This ﬁnding indicates that the stimula-
tory effect of palmitate on TLR4-driven signaling in human
muscle is common to other saturated fatty acids.
TLR4 mediates the effect of palmitate on IB/NFB
signaling. The role of TLR4 in the activation of IB/NFB
by FFAs was assessed by blocking TLR4. Preincubation of
human myotubes with TLR4 neutralizing antibodies pre-
vented the ability of palmitate to phosphorylate IB (Fig.
4A), whereas antibodies against TLR2 did not block the
stimulatory effect of palmitate (Fig. 4B).
Prolonged FFA exposure increases TLR4 expression.
Because plasma FFA, insulin, TNF-, and IL-6 concentra-
tions are typically elevated in insulin-resistant subjects, we
examined whether these factors had any effect on muscle
TLR4 content. Figure 5A shows that a 3-day exposure to
palmitate caused a signiﬁcant increase in TLR4 protein
content in human myotubes. In contrast to palmitate,
chronic exposure to insulin, TNF-, or IL-6 did not in-
crease TLR4 protein content (not shown). Consistent with
the elevation in TLR4 protein content, treatment with
palmitate for 6 h also increased TLR4 gene expression
(Fig. 5B). Importantly, this effect was reproduced by
stimulating the cells with synthetic monophosphoryl-lipid
A (Fig. 5C), a speciﬁc TLR4 agonist (32).
The proinﬂammatory effect of palmitate is NFB
mediated. An IB supperrepressor mutant was used to
examine whether the effect of palmitate on IL-6, SOD2, and
TLR4 mRNA expression is mediated by NFB. As shown in
Isotype Control Anti -TLR2
0
1
2
3 * ‡
Isotype Control Anti -TLR2 
BSA Palm BSA Palm
Isotype Control Anti -TLR4
0
1
2
3
4
5
6 *
BSA            Palm             BSA           Palm
BSA            Palm             BSA           Palm
P
-
I
κ
B
α
 
(
f
o
l
d
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
a
l
)
P
-
I
κ
B
α
 
(
f
o
l
d
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
a
l
)
P-IκBα
P-IκBα
Isotype Control Anti -TLR4 
†
BSA Palm BSA Palm
A
B
FIG. 4. Effect of TLR neutralizing antibodies. Human myotubes were
incubated with TLR4 (A) or TLR2 (B) neutralizing antibodies for 1 h
and then stimulated with 400 mol/l palmitate (Palm) for 1 h. Data are
means  SE, n  6–9 per group. *P < 0.05 vs. BSA of isotype control
group, †P < 0.05 vs. palmitate of isotype control group, and ‡P < 0.05
vs. BSA of anti-TLR2 group.
BSA Palm
TLR4
0
0.5
1.5
T
L
R
4
 
p
r
o
t
e
i
n
 
c
o
n
t
e
n
t
 
(
f
o
l
d
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
a
l
)
T
L
R
4
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
f
o
l
d
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
a
l
)
T
L
R
4
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
f
o
l
d
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
a
l
)
1
BSA Palm 
β-actin
0
0.5
1
2
3
1.5
2.5
BSA Palm
100
97
54
0
0.5
1
1.5
2
2.5
Control Lipid A
*
*
*
A
B
C
D
FIG. 5. Palmitate (Palm) increases TLR4 content and gene expression.
Human myotubes were incubated with 200 mol/l palmitate for 3 days
(A)o r6h( B), and TLR4 protein content (A) and mRNA expression (B)
were measured by Western blotting and real-time PCR, respectively.
TLR4 gene expression was measured after treating myotubes with
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stimulated NFB activity (Fig. 6B), and increased the gene
expression of IL-6 (Fig. 6C) and SOD2 (Fig. 6D), effects
that were blocked by the IB supperrepressor. Palmi-
tate-induced TLR4 gene expression was also blocked by
inhibiting NFB through overexpression of the IB
supperrepressor (Fig. 6E), but not by preincubating the
cells with TLR4-neutralizing antibodies (not shown).
DISCUSSION
The main ﬁnding of this study is that obese and type 2
diabetic subjects have increased TLR4 gene expression/
content and TLR4-driven (IB/NFB) signaling in skeletal
muscle. To examine whether FFAs directly activate TLR4
signaling in human muscle, myotubes were treated with
palmitate, which rapidly stimulated the IB/NFB cas-
cade. Furthermore, blocking TLR4 completely inhibited
the ability of palmitate to stimulate this pathway. Because
most obese nondiabetic and type 2 diabetic subjects have
elevated plasma FFA concentrations (33), our results
suggest that TLR4 may play an important pathogenic role
in the mechanism by which FFAs induce an inﬂammatory
response in insulin-resistant subjects.
To elucidate the cause for the elevation in TLR4 content
present in the muscle from the obese and type 2 diabetic
subjects, human myotubes were treated with palmitate for
3 days. Chronic palmitate treatment caused a signiﬁcant
increase in myotube TLR4 content, whereas prolonged
exposure to insulin, TNF-, or IL-6, whose plasma concen-
trations are typically elevated in insulin-resistant (obese
and type 2 diabetic) subjects, had no effect. In line with
this ﬁnding, palmitate increased TLR4 gene expression, an
effect that was mediated via NFB. Consistent with inves-
tigations performed in human endothelial cells that
showed that LPS increases TLR4 expression (34), we
found that treatment with the speciﬁc TLR4 agonist
monophosphoryl lipid A also induces TLR4 gene expres-
sion in human myotubes. This suggests that palmitate-
induced TLR4 gene expression is dependent on TLR4
activation. Nonetheless, this effect was not inhibited by
TLR4-neutralizing antibodies, suggesting that, in addi-
tion to TLR4 stimulation, other mechanisms, such as
accumulation of intracellular lipids (ceramides and di-
acylglycerol), may be involved in FFA-induced TLR4
expression. Because the elevations in TLR4 expression/
content in the muscle from insulin-resistant subjects
were reproduced in myotubes by prolonged exposure to
palmitate, one could speculate that these increases in
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FIG. 6. Palmitate induces an inﬂammatory response via NFB.
Human myotubes were transduced with adenovirus-IB supperre-
pressor (SR)-HA or adenovirus-GFP for 4 h, and 48 h later, cells
were stimulated with 200 mol/l palmitate for 6 h. IB was
detected by Western blotting (A), NFB p65 activity was measured
by ELISA (B), and IL-6 (C), SOD2 (D), and TLR4 (E) gene
expression were quantitated by real-time PCR. Data are means 
SE, n  9 per group. *P < 0.05 vs. BSA of GFP group and †P < 0.05
vs. palmitate of GFP group.
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ary to excess FFA supply. Nonetheless, future studies
will be needed to establish whether there also is a
genetic (inherited) basis underlying the elevation in
TLR4 expression in insulin-resistant muscle.
Senn (35) reported that TLR2, another member of the
TLR family, is involved in palmitate-induced insulin resis-
tance in mouse-derived C2C12 myotubes. To examine this
possibility in humans, we measured TLR2 gene expression
in muscle from insulin-resistant subjects. Both obese and
type 2 diabetic individuals displayed elevated TLR2 gene
expression in muscle. However, TLR2 protein was not
detected in muscle by direct Western blotting, although a
signal (too weak for quantitation) corresponding to TLR2
was detected after immunoprecipitation. Taking into ac-
count that absolute mRNA levels of TLR4 versus TLR2 in
human muscle were roughly similar (not shown), the low
TLR2 protein content observed in human muscle is likely
due to post-transcriptional regulation and/or protein insta-
bility (i.e., degradation). Poor antibody immunoefﬁciency
could be another reason for the low TLR2 protein content
observed in human muscle, although this seems unlikely
considering that TLR2 protein was readily detectable in
human mononuclear cells. Importantly, TLR2 neutralizing
antibodies did not affect the ability of palmitate to activate
IB/NFB signaling. Based on these results, it is unlikely
that TLR2 plays a major role in lipid-induced insulin
resistance in human muscle.
Another relevant ﬁnding in this study is the increased
gene expression of the inﬂammatory proteins IL-6 and
SOD2 in the muscle from obese and type 2 diabetic
subjects. Experiments performed in monocyte-like (U937)
cells (12) and ﬁbroblasts (13) have demonstrated that the
expression of these proteins is regulated by NFB. Human
myotubes were treated with palmitate to explore whether
elevated circulating FFA levels in obese and type 2 dia-
betic subjects might be responsible for the increased gene
expression of IL-6 and SOD2 in muscle. Palmitate robustly
increased mRNA expression of IL-6 and SOD2 in the
myotubes. Moreover, blockade of NFB completely
blocked the ability of palmitate to induce the gene expres-
sion of these inﬂammatory proteins. Therefore, elevation
in plasma FFA concentration may contribute to increased
gene expression of IL-6 and SOD2 in muscle from insulin-
resistant subjects, and this effect is likely mediated by
NFB.
Accumulating evidence suggests that monocytes/macro-
phages play an important role in the pathogenesis of
insulin resistance by inﬁltrating insulin-sensitive tissues,
such as muscle and fat (36,37). Thus, it is possible that the
increases in TLR4 expression and signaling observed in
the muscle tissue from insulin-resistant subjects are due to
inﬂammatory cell inﬁltration of the muscle, rather than
from intrinsic upregulation of TLR4 expression/signaling
within the myoﬁbers. For this reason, we performed
Western analysis and real-time PCR of EMR1, a marker for
monocyte/macrophage inﬁltration, in muscle tissue of
insulin-resistant subjects and in cultured myotubes. Unlike
CD14
 monocytes (AllCells, Emeryville, CA), which ex-
pressed EMR1, neither EMR1 protein nor mRNA was
detected in the muscle tissue or myotubes (not shown). It
is therefore unlikely that the differences in TLR4 expres-
sion/signaling observed between groups are secondary to
monocyte/macrophage inﬁltration of muscle.
In conclusion, insulin-resistant subjects have increased
TLR4-driven signaling in muscle. We propose a model in
which elevated plasma FFA levels in obese and type 2
diabetic subjects activates this signaling pathway by 1)
directly interacting (binding) with TLR4 and 2) increasing
TLR4 gene expression and protein content, leading to a net
increase in the number of TLR4 receptors available for
stimulation by elevated plasma FFA levels. Strategies
aimed at reducing TLR4 expression, or at blocking TLR4
signaling, may prove useful in enhancing insulin sensitivity
in insulin-resistant individuals.
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